Last reviewed · How we verify
NCT06972498
A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets
Phase 2 trial testing Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively. in Colorectal Cancer With Liver Metastasis in 35 participants. Not yet recruiting.
30 December 2027
Quick facts
| Lead sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 1 July 2025 |
| Primary completion | 30 December 2027 |
| Estimated completion | 30 December 2027 |
Drugs / interventions tested
- Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.
Conditions studied
- Colorectal Cancer With Liver Metastasis — all drugs for Colorectal Cancer With Liver Metastasis →
Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Who can join
Adults 18 to 75, any sex, with Colorectal Cancer With Liver Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06972498
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials
Trials by the same sponsor.
- NCT07336888 — A Study on the Application of Positive Psychological Counseling Based on "Dou Bao" Software in Patients With Post-stroke · NA · not yet recruiting
- NCT07375862 — Investigating the Clinical Benefits and Underlying Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostas · Phase 2 · not yet recruiting
- NCT07301437 — RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. · Phase 4 · not yet recruiting
- NCT07289750 — The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients · Phase 4 · not yet recruiting
- NCT07512791 — Effect of Bagua Auriculotherapy on Pain in Patients Undergoing Hysteroscopy · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06972498 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Last refreshed: 15 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06972498.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing